Entrada Therapeutics, Inc. Contracts & Agreements
35 Contracts & Agreements
- Business Finance (8 contracts)
- Business Operations (8)
- Human Resources (9)
- Intellectual Property (3)
- Real Estate (2)
- Uncategorized (5)
- Form of Pre-Funded Warrant (Filed With SEC on June 24, 2024)
- Securities Purchase Agreement, dated June 24, 2024, by and among Entrada Therapeutics, Inc. and purchasers named therein (Filed With SEC on June 24, 2024)
- Affiliate Registration Rights Agreement, dated June 24, 2024, by and among Entrada Therapeutics, Inc. and Baker Brothers Life Sciences, L.P. and 667, L.P (Filed With SEC on June 24, 2024)
- Exclusive License Agreement, by and between the Registrant and (Filed With SEC on March 13, 2024)
- Lease Agreement, date (Filed With SEC on March 13, 2024)
- Strategic Collaboration and License Agreement, dated December 7, 2022, by and between the Registrant and Vertex Pharmaceuticals Incorporated (Filed With SEC on March 13, 2024)
- Sublicense Agreement dated December 7, 2022, by and between the Registrant and Vertex Pharmaceuticals Incorporated (Filed With SEC on March 13, 2024)
- Amendment to Strategic Collaboration and License Agreement, dated October 26, 2023, by and between Entrada Therapeutics, Inc. and Vertex Pharmaceuticals Incorporated (Filed With SEC on November 1, 2023)
- Amendment to Sublicense Agreement, dated October 26, 2023, by and between Entrada Therapeutics, Inc. and Vertex Pharmaceuticals Incorporated (Filed With SEC on November 1, 2023)
- Sales Agreement, by and between Entrada Therapeutics, Inc. and Cowen and Company, LLC, dated as of September 29, 2023 (Filed With SEC on September 29, 2023)
- Strategic Collaboration and License Agreement, dated December 7, 2022, by and between the Registrant and Vertex Pharmaceuticals Incorporated (Filed With SEC on May 10, 2023)
- Sublicense Agreement dated December 7, 2022, by and between the Registrant and Vertex Pharmaceuticals Incorporated (Filed With SEC on May 10, 2023)
- Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on May 10, 2023)
- Strategic Collaboration and License Agreement, dated December 7, 2022, by and between the Registrant and Vertex Pharmaceuticals Incorporated (Filed With SEC on March 6, 2023)
- Sublicense Agreement dated December 7, 2022, by and between the Registrant and Vertex Pharmaceuticals Incorporated (Filed With SEC on March 6, 2023)
- Stock Purchase Agreement, dated December 7, 2022, by and between Entrada Therapeutics, Inc. and Vertex Pharmaceuticals Incorporated (Filed With SEC on December 8, 2022)
- Lease Agreement, dated March 16, 2022 between IDB 17-19 Drydock Limited Partnership and Entrada Therapeutics, Inc (Filed With SEC on March 22, 2022)
- Description of Securities of the Registrant (Filed With SEC on March 15, 2022)
- Specimen Common Stock Certificate (Filed With SEC on October 25, 2021)
- 2021 Stock Option and Incentive Plan and form of award agreements thereunder (Filed With SEC on October 25, 2021)
- 2021 Employee Stock Purchase Plan (Filed With SEC on October 25, 2021)
- Form of Indemnification Agreement between the Registrant and each of its directors (Filed With SEC on October 25, 2021)
- Form of Indemnification Agreement between the Registrant and each of its executive officers (Filed With SEC on October 25, 2021)
- Senior Executive Cash Incentive Bonus Plan (Filed With SEC on October 25, 2021)
- Form of Executive Employment Agreement (Filed With SEC on October 25, 2021)
- Non-Employee Director Compensation Policy (Filed With SEC on October 25, 2021)
- Amended and Restated Employment Agreement, by and between the Registrant and Dipal Doshi, to be in effect as of the closing of this offering (Filed With SEC on October 25, 2021)
- Amended and Restated Employment Agreement, by and between the Registrant and Natarajan Sethuraman, to be in effect as of the closing of this offering (Filed With SEC on October 25, 2021)
- Amended and Restated Employment Agreement, by and between the Registrant and Nathan Dowden, to be in effect as of the closing of this offering (Filed With SEC on October 25, 2021)
- Amended and Restated Strategic Advisory Agreement, by and between the Registrant and Peter S. Kim, to be in effect as of the closing of this offering (Filed With SEC on October 25, 2021)
- Form of Underwriting Agreement (Filed With SEC on October 8, 2021)
- Amended and Restated Investors Rights Agreement among the Registrant and certain of (Filed With SEC on October 8, 2021)
- 2016 Stock Incentive Plan, as amended, and form of award agreements thereunder (Filed With SEC on October 8, 2021)
- Exclusive License Agreement, by and between the Registrant and OSIF, dated as of December 14, 2018, as amended on October 8, 2019 and further amended on March 9, 2019 (Filed With SEC on October 8, 2021)
- License Agreement (Filed With SEC on October 8, 2021)
